Background {#Sec1}
==========

Coronavirus disease-19 (COVID-19)---also known as 2019 novel coronavirus---has infected more than 2 million people in the world in less than 5 months, with almost 160 thousands deaths \[[@CR1]\]. Patients with COVID-19 can progress from asymptomatic or mild disease to hypoxemic respiratory failure or multisystem organ failure, requiring intubation and intensive care management \[[@CR2]\].

The lung is the predominant disease site in COVID-19 infection and may lead to the so-called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection \[[@CR2]\]. COVID-19 infects human cells through its spike surface glycoprotein that binds to the receptor-binding domains of the angiotensin converting enzyme 2 (ACE2), which is abundant in epithelial cells of the tongue and type II alveolar cells \[[@CR3], [@CR4]\]. After binding to the ciliated cells in the alveoli, the virion releases RNA into the cell, initiating replication of the virus which further disseminates to infect other cells. As a consequence, the infected cells likely stop clearing the airways with a consequent progressive accumulation of debris and fluids in the lungs \[[@CR5]--[@CR7]\]. The first non-severe stage of lung involvement by COVID-19, with only mild symptoms, may be attributed to the direct viral damage and innate immune response. The second severe stage, with progressive hypoxemic respiratory failure, may be attributed to tissue damage by specific immune response (the so-called cytokine release syndrome) \[[@CR8]\]. Imaging allows to identify and grade the extent of the COVID-19 disease \[[@CR2]\]. In this essay, we collected the imaging and clinical experience from multiple Italian centers involved in the COVID-19 outbreak, including two nonacademic hospitals and one academic hospital in Lombardy (the most affected Italian region) that acquired each about 30--60 radiographies and CT scans per day in COVID-19 patients and one academic hospital in Sicily (one of the least affected Italian region).

The aim of this pictorial essay is to illustrate the imaging presentation of COVID-19 pneumonia, including identification of typical and uncommon imaging findings at diagnosis and follow-up and the role of imaging features for patient management**.**

Imaging presentation and follow-up of COVID-19 pneumonia {#Sec2}
========================================================

Imaging modalities {#Sec3}
------------------

Imaging assessment of COVID-19 pneumonia has been performed with different modalities, including ultrasound (US), chest radiographs (CXR), and computed tomography (CT). The choice of imaging technique depends on equipment availability and clinical context, as well as national/regional needs and recommendations \[[@CR2], [@CR9]\]. Lung ultrasound has been proposed in suspected COVID-19 patients as a potential triage and diagnostic tool in tents or other areas outside hospitals where other imaging modalities are not available because it allows to rapidly triage patients through the identification of thickened and irregular pleural line and B lines in a variety of patterns \[[@CR9], [@CR10]\]. We speculated that it could be useful also in monitoring hospitalized ventilated or intubated COVID-19 patients. However, in our experience, CXR and CT scan were performed rather than lung ultrasound in hospitalized patients to monitor lung involvement. Indeed, ultrasound has a limited sensitivity and specificity for the assessment of lung diseases because it has a limited capability in detecting pulmonary lesions that are deep and intrapulmonary and ultrasound findings of COVID-19 overlap with those from other viral pneumonia. CXR and CT are currently used in patients with suspected or confirmed COVID-19 pneumonia \[[@CR2]\]. Baseline CXR and chest CT have a sensitivity of 69% and 97% for the diagnosis of COVID-19, respectively (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR11]--[@CR13]\]. CT may allow to detect COVID-19 pneumonia even before real-time PCR \[[@CR12], [@CR13]\]. However, the huge drawback of CT is its low specificity (i.e., 25--56%) for COVID-19 pneumonia \[[@CR12], [@CR13]\], due to overlapping of imaging features with other viral or atypical pneumonia \[[@CR14], [@CR15]\].Fig. 1A 56-year-old man with fever, cough, and positive for COVID-19. Chest radiograph (**a**, **b**) shows no significant lung abnormalities. Coronal (**c**) and sagittal (**d**) CT images demonstrate subpleural consolidations and ground-glass opacities in the right lower lobe (arrows)

Indications to imaging assessment {#Sec4}
---------------------------------

The use of imaging in suspected cases of COVID-19 pneumonia is currently debated, with some authors highlighting the high sensitivity of CT \[[@CR12], [@CR13]\] and others showing that its routine use should be avoided given its low specificity \[[@CR14], [@CR15]\]. A multinational consensus statement from the Fleischner Society issued on April 2020 has recommended to avoid any imaging in suspected cases of COVID-19 and mild clinical symptoms unless there is any risk for disease progression and has indicated imaging only for medical triage of suspected cases of COVID-19 who present with moderate-severe clinical features and a high pre-test probability of disease \[[@CR2]\]. In addition, imaging is indicated in patients with functional impairment after recovery to differentiate between expected abnormalities following COVID-19 infection and/or mechanical ventilation, versus a different and potentially treatable process \[[@CR2]\].

Chest CT is indicated and widely adopted as first-line imaging technique in suspected cases of COVID-19 who present with moderate-severe clinical features and high pre-test probability of disease as well as in confirmed symptomatic cases \[[@CR2], [@CR16]\]. Considering its high sensitivity, it is also questioned whether chest CT should be used as a screening tool in highly prevalent areas either as a stand-alone or as an adjunct to real-time PCR to exclude occult infection prior to surgery or intensive immunosuppressive therapies \[[@CR2]\].

CXR is of little diagnostic value in early stages due to the low sensitivity (Fig. [1](#Fig1){ref-type="fig"}) and it is not indicated in the early course of the disease, except in resource-constrained environments with very high number of suspected COVID-19 symptomatic patients, long real-time PCR turnaround times, and lack of possibility to supersede chest radiographs by CT \[[@CR2], [@CR17]\]. CXR has a pivotal role in hospitalized patients for assessing disease progression, bacterial superinfection, pneumothorax, and pleural effusion \[[@CR2]\]. In the intermediate to advanced stages of the disease, CXR may show progression of imaging features of acute respiratory distress syndrome in intensive care unit (ICU) patients (Fig. [2](#Fig2){ref-type="fig"}) and may help in guiding patient management \[[@CR17]\]. However, CXR is not needed on a daily basis in stable intubated patients in ICU as there is no impact on important outcomes (mortality, length of stay, and ventilator days) as compared with on-demand CXR \[[@CR18], [@CR19]\].Fig. 2A 72-year-old man with fever and cough for 7 days and COVID-19 pneumonia in chest imaging. Serial chest radiographs performed at admission (**a**), 12 h after tracheal intubation in ICU (**b**), 5 days (**c**), 10 days (**d**), and 12-days (**e**) of ICU demonstrate progressive worsening of the bilateral lung opacities and consolidations

CXR and CT imaging findings {#Sec5}
---------------------------

The characteristic CT manifestations of COVID-19 pneumonia most commonly include bilateral and multilobar ground-glass opacities (GGO) with peripheral distribution (Fig. [3a](#Fig3){ref-type="fig"}) \[[@CR17]\]. Interestingly, a common and typical finding of COVID-19 pneumonia is the presence of subsegmental vessel enlargement (\> 3 mm) (Fig. [3b](#Fig3){ref-type="fig"}) and traction bronchiectasis within areas of GGO (Fig. [3b](#Fig3){ref-type="fig"}) \[[@CR13], [@CR20]\]. The "reversed halo" sign, pulmonary nodules with a halo sign (Fig. [4a](#Fig4){ref-type="fig"}) and pleural effusion (Fig. [4b](#Fig4){ref-type="fig"}) may be present but are uncommon CT features in COVID-19 \[[@CR16]\].Fig. 3Typical imaging findings of COVID-19 pneumonia on chest CT. **a** A 72-year-old man with COVID-19 infection: chest CT shows bilateral peripheral ground-glass opacities. **b** A 67-year-old man with COVID-19 infection: chest CT demonstrates extensive bilateral ground-glass opacities with subsegmental vessel enlargement (arrowheads) and traction bronchiectasis (arrows)Fig. 4Uncommon imaging findings of COVID-19 pneumonia on chest CT: halo sign and pleural effusion. **a** A 58-year-old man with COVID-19 infection: chest CT shows typical halo sign (arrow) characterized by a nodule surrounded by ground-glass opacity. **b** A 67-year-old woman with COVID-19 infection: chest CT demonstrates ground-glass opacities in the inferior lobes and mild bilateral pleural effusion

CT findings of COVID-19 pneumonia vary with time \[[@CR21]\] and different temporal stages have been described \[[@CR15], [@CR22]\] as follows:An ultra-early stage---i.e., asymptomatic patients with negative laboratory test but positive throat swab for 2019-nCoV within 1--2 weeks from COVID-19 infection---that demonstrates on CT single or few focal GGO, patchy consolidation, pulmonary nodules encircled by GGO, and air bronchograms (Fig. [5](#Fig5){ref-type="fig"})An early stage (1--3 days from onset of symptoms) when dilatation and congestion of alveolar septal capillary, exudation of fluid in alveolar cavity, and interlobular interstitial edema result into single or multiple scattered patchy or agglomerated GGO, separated by honeycomb-like or grid-like thickened of interlobular septa; of note, thickened interlobular and intralobular lines in combination with GGO is known as "crazy paving" pattern (Fig. [6](#Fig6){ref-type="fig"})A rapid progression (3--7 days from onset of symptoms) when accumulation of a large number of cell-rich exudates in the alveoli, vascular expansion and interstitial exudation result into large, light consolidative opacities with air bronchograms (Fig. [7](#Fig7){ref-type="fig"})A consolidation stage (7--14 days from onset of symptoms) when fibrous exudation of the alveolar cavity and disappearance of capillary congestion in the alveolar wall result into multiple patchy consolidations, and a progressive reduction in density and size of the consolidative opacities may be seen (Fig. [8](#Fig8){ref-type="fig"})A dissipation stage (2--3 weeks from onset of symptoms) with grid-like thickening of interlobular septa, dispersed patchy consolidative opacities, reticular opacities, and bronchial wall thickening (Fig. [9](#Fig9){ref-type="fig"})Fig. 5Chest CT imaging findings in the ultra-early stage in six different patients with COVID-19 pneumonia range from single (**a**) or few (**b**, **c**, **d**) ground-glass opacities (frames) to focal small consolidations (**e**, **f**; arrows)Fig. 6Chest CT imaging findings in the early stage of COVID-19 pneumonia. Chest CT in an 80-year-old man with fever since 8 days (**a**, **b**) and in a 78-year-old man (**c**, **d**) in the coronal (**a**, **c**) and axial (**b**, **d**) planes show extensive reticular pattern superimposed on the background of ground-glass opacity in the bilateral lungs, predominantly located in the upper lobes. Patient 1 (**a**, **b**) died after 3 daysFig. 7Chest CT imaging findings in the rapid progression stage of COVID-19 pneumonia. Chest CT images in a 73-year-old man (**a**) and in a 59-year-old woman (**b**) show rapid progression from ground-glass opacities to consolidative opacities (frames), some with air bronchograms (**b**)Fig. 8Chest CT imaging findings in the consolidative stage of COVID-19 pneumonia in three different patients demonstrate multiple subpleural patchy consolidations in the bilateral lungsFig. 9A 78-year-old man with COVID-19 in dissipation stage. Axial chest CT shows interlobular septa thickening and reticular opacities (frame) after COVID-19 pneumonia

CXR shows similar findings of CT including bilateral pneumonia in about 63--73% of hospitalized patients, with interstitial infiltrates in 41--68% of the patients, peripheral distribution in 51% of the cases, with predominant involvement of the lower lung zones in 63% (Fig. [10](#Fig10){ref-type="fig"}) \[[@CR11], [@CR23]\]. CXR findings in COVID-19 patients may present with an interstitial pattern (Fig. [11a](#Fig11){ref-type="fig"}) with reticular or reticulonodular hypodiaphany and oftentimes Kerley lines that are perpendicular to the pleura and indicate interstitial thickening, a consolidative pattern with ill-defined hypodiaphania including ground-glass opacification (Fig. [11b](#Fig11){ref-type="fig"})---a term usually used on CT to describe to an area of increased attenuation with preserved bronchial and vascular markings---or homogeneous opacification with air bronchogram, or a combination of the reticular and consolidative patterns (Fig. [11c](#Fig11){ref-type="fig"}).Fig. 10Typical imaging findings of COVID-19 pneumonia on chest radiographs. A 58-year-old woman with COVID-19 infection: chest radiograph shows bilateral ground-glass opacities (frames) with predominant peripheral locationFig. 11Chest radiograph patterns of COVID-19 pneumonia. **a** An 84-year-old man with hypotension and dyspnea since 7 days: CXR shows Kerley lines (frames) perpendicular to the pleura. **b** 68-year-old man with dyspnea and fever since 7 days and who died after 5 days: CXR shows consolidative pattern and ground-glass opacities. **c** A 55-year-old man with fever and dyspnea since 4 days: CXR shows combination of the reticular and consolidative patterns (frame)

The severity and extent of the disease during hospitalization may be assessed using a CXR severity score obtained by adapting and simplifying the radiographic assessment of lung edema (RALE) score proposed by Warren et al. \[[@CR24]\] and modified by Wong et al. \[[@CR11]\]. According to this CXR severity score, a score of 0--4 is assigned to each lung depending on the extent of involvement by consolidation or ground-glass opacities (0: no involvement; 1: \< 25%; 2: 25--50%; 3: 50--75%; 4: \> 75% involvement), and then the scores for each lung is summed to produce the final severity score \[[@CR11]\]. The CXR severity score is not routinely used in the majority of radiology departments, but it is the authors' opinion that if this score is included in radiology reports, it could potentially simplify COVID-19 disease monitoring for clinicians. The peak severity according to CXR severity score in COVID-19 patients is reached at 10--12 days \[[@CR11]\].

Imaging for patient management {#Sec6}
------------------------------

The description of CT pattern may have important implications for patient management. To date, about 3% of currently infected patients has serious or critical conditions \[[@CR25]\], and about 17% of hospitalized patients needs ICU admission \[[@CR26], [@CR27]\]. Radiologists may be helpful in identifying patients at higher risk of lung disease worsening. Indeed, the presence of tubular size increase of pulmonary segmental vessel around and within the lesions with normally ventilated adjacent lung parenchyma (Fig. [12](#Fig12){ref-type="fig"}) has been suggested as an early alert radiological sign to predict initial lung deterioration \[[@CR28]\]. Indeed, some authors believe that the presence of enlarged pulmonary vessels may indicate an inflammatory cell infiltration of the vessels \[[@CR29]\] or might be due to pro-inflammatory factors \[[@CR30]\], thus potentially indicating that the patient is in the second stage of COVID-19 lung involvement.Fig. 12An 83-year-old woman with COVID-19 pneumonia. Chest CT angiography reconstructed using maximum intensity projection (MIP) demonstrates enlargement of pulmonary segmental vessel and peripheral ground-glass opacities

Chest CT may help in guiding therapeutic strategy. CXR and CT may demonstrate findings of acute respiratory distress syndrome (ARDS) (Fig. [13](#Fig13){ref-type="fig"}) including bilateral opacities, not fully explained by volume overload, lobar or lung collapse, or nodules \[[@CR31]\]. The most common CT finding of ARDS is the presence of large lung infiltrates with loss of ventilation, especially in the posterior and basal regions, with ground-glass opacities alternating with consolidations \[[@CR32]\]. However, imaging findings of ARDS vary depending on the stage of the disease ranging from an exudative acute phase in the first week characterized by bilateral and symmetrical air space and interstitial opacities on CXR, and opacifications showing an antero-posterior density gradient characterized by dense bilateral consolidation in the dependent lung and a background of widespread GGO or normal lung in the non-depended portions of the lung, to a proliferative intermediate phase in the second week with overall stability of the imaging findings and a fibrotic late phase after 2 weeks with normal or reticular opacities on CXR, and eventually a coarse reticular pattern with areas of fine fibrosis on CT (Fig. [14](#Fig14){ref-type="fig"}) \[[@CR32]\]. It is important to identify patients with COVID-19 pneumonia progressing to ARDS because these patients could benefit from corticosteroid treatment according to Xu et al. \[[@CR6]\]. In addition, in patients with severe ARDS, prone ventilation for 12--16 h per day is indicated by World Health Organization Interim guidance because it improves oxygenation and respiratory compliance compared with supine positioning \[[@CR33], [@CR34]\]. Chest imaging is also considered important in World Health Organization Interim guidance V 1.2 when findings of pulmonary edema are evident because, in these cases, it is indicated to reduce or discontinue fluid administration to avoid volume overload \[[@CR33]\].Fig. 13An 85-year-old woman with worsening dyspnea since 7 days, history of arterial hypertension, lymphopenia, and with COVID-19 pneumonia progressed to acute respiratory distress syndrome. Chest radiograph (**a**), axial (**b**), and coronal (**c**) CT images show extensive ground-glass opacities alternating with consolidations in both lungs. The patient died 2 days after CTFig. 14An 85-year-old woman with fever, cough, and dyspnea images after 2 weeks of COVID-19 infection. Axial chest CT shows coarse reticular pattern with areas of fine fibrosis in both lungs

Conclusions {#Sec7}
===========

To conclude, imaging appearance of COVID-19 pneumonia may vary depending on the stage of the disease. CT is indicated for medical triage of suspected cases of COVID-19 who present with moderate-severe clinical features and a high pre-test probability of disease and may be useful in hospitalized patients to identify signs that indicate potential lung disease worsening. Chest radiographs are more commonly used for assessing disease progression, bacterial superinfection, pneumothorax, and pleural effusion. A comprehensive knowledge of the typical findings of COVID-19 pneumonia in the different stages is of utmost importance because some of the imaging findings have a translational importance in clinical practice for patient therapy.
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